zacks.com · 1 jul

SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study

Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.

globenewswire.com · 1 jul

Press Release: Availability of the aide-mémoire for Q2 2026 results

Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.

fool.com · 30 jun

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows

When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typical yields. The stocks listed here haven't been doing well this year, but they offer some attractive dividend income.

fool.com · 30 jun

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

reuters.com · 26 jun

EU Commission opens antitrust probe into Sanofi's flu vaccine campaign

The European Commission opened on Friday an ​investigation into whether French ‌drug giant Sanofi breached EU competition rules in a flu ​vaccine marketing campaign.

fool.com · 25 jun

Is AbbVie a Buy After Its Purchase of Apogee?

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

seekingalpha.com · 25 jun

Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity

Sanofi is reiterated as a compelling buy, trading at a pronounced valuation discount versus pharma peers despite solid results and strategic focus. Dupixent drives 40% of Sanofi's sales and 80% of Q1 incremental growth; management is pursuing lifecycle management to mitigate 2031 U.S. LOE risk. Dupixent concentration is not unique. Management continues to pursue lifecycle management initiatives, including new formulations and a hyaluronidase co-formulation, while planning conservatively under a no-extension scenario.

globenewswire.com · 25 jun

Press Release: Sanofi Foundation opens new chapter centered on future generations

Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those living with serious diseases.